Finerenone (Kerendia, BAY948862) Clinical Trials (2026): 4 Studies for Chronic Kidney Disease & Type 2 Diabetes Mellitus
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 Finerenone (Kerendia, BAY948862) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Chronic Kidney Disease & Type 2 Diabetes Mellitus) and 173,685 total planned enrollment. Most recent activity: NCT06763146 (Jun 2026).
Finerenone (Kerendia, BAY948862) clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | Total |
|---|---|---|---|
| N/A | 2 | 2 | 4 |
All Finerenone (Kerendia, BAY948862) trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06763146 | IN-REALITY | An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | — | active not recruiting | 1,200 | Bayer | Sep 2025 |
| NCT06608212 | An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States | — | active not recruiting | 150,000 | Bayer | Oct 2024 | |
| NCT07124039 | FIRST-2_CN | An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population. | — | completed | 6,537 | Bayer | Jul 2025 |
| NCT05703880 | FIRST-2 | An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | — | completed | 15,948 | Bayer | Jun 2023 |
Finerenone (Kerendia, BAY948862) clinical trials: frequently asked questions
- How many Finerenone (Kerendia, BAY948862) clinical trials are there?
- 4 Finerenone (Kerendia, BAY948862) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
- Are Finerenone (Kerendia, BAY948862) clinical trials recruiting in 2026?
- No active Finerenone (Kerendia, BAY948862) trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Finerenone (Kerendia, BAY948862) being studied for?
- Finerenone (Kerendia, BAY948862) is being studied for Chronic Kidney Disease, Type 2 Diabetes Mellitus. The trials are grouped by indication on this page.
- Who sponsors Finerenone (Kerendia, BAY948862) clinical trials?
- The lead sponsor across the most Finerenone (Kerendia, BAY948862) trials is Bayer. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Finerenone (Kerendia, BAY948862)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: